FDA.reportPublic FDA data

lebrikizumab-lbkz 250 MG per 2 ML Pen Injector

RxCUI
2693903
RxNorm name
lebrikizumab-lbkz 250 MG per 2 ML Pen Injector
Display name
lebrikizumab-lbkz 250 MG per 2 ML Pen Injector
Full name
lebrikizumab-lbkz 250 MG per 2 ML Pen Injector
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:05

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761306Ebglysslebrikizumab-lbkz351(a)Rx2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
EBGLYSSLEBRIKIZUMAB-LBKZEli Lilly and Company7a774ea2-acde-4aaa-9a8f-ccba5a5b1d5f2026-06-09Warnings, Adverse reactionsExact identifier
rxcui: 2693903

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
7a774ea2-acde-4aaa-9a8f-ccba5a5b1d5flebrikizumab-lbkz 250 MG per 2 ML Pen InjectorSY12These highlights do not include all the information needed to use EBGLYSS safely and effectively. See full prescribing information for EBGLYSS. EBGLYSS (lebrikizumab-lbkz), injection, for subcutaneous use Initial U.S. Approval: 202420260520
7a774ea2-acde-4aaa-9a8f-ccba5a5b1d5flebrikizumab-lbkz 250 MG in 2 ML Pen InjectorPSN12These highlights do not include all the information needed to use EBGLYSS safely and effectively. See full prescribing information for EBGLYSS. EBGLYSS (lebrikizumab-lbkz), injection, for subcutaneous use Initial U.S. Approval: 202420260520
7a774ea2-acde-4aaa-9a8f-ccba5a5b1d5f2 ML lebrikizumab-lbkz 125 MG/ML Pen InjectorSCD12These highlights do not include all the information needed to use EBGLYSS safely and effectively. See full prescribing information for EBGLYSS. EBGLYSS (lebrikizumab-lbkz), injection, for subcutaneous use Initial U.S. Approval: 202420260520